Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/03/2026 ,inter alia, to consider and approve the Scheme of Arrangement (demerger)
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Natco Pharma has informed BSE that its Board of Directors will meet on 24 March 2026 to consider and approve a Scheme of Arrangement involving a demerger. The company has not disclosed further details such as which business vertical will be demerged, the swap ratio, or the timeline for filings. Until the board meeting takes place and detailed terms are shared with the stock exchanges and shareholders, the structure and scale of this corporate restructuring remain unclear. Investors will need to wait for the post-meeting outcome for concrete information.
In the short term, the stock may see some speculative interest leading up to the board meeting on 24 March 2026. The actual impact on shareholders will depend on the demerger ratio, the valuation of the spun-off business, and whether shareholders receive shares in the new entity. Watch for the company's detailed announcement after the board meeting for clarity.